Abigail L. Hulsizer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Abigail L. Hulsizer has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Adenike Atanda
Department of Pharmacotherapy, UNT System College of Pharmacy, 3500 Camp Bowie Blvd, Fort Worth, TX, 76107, USA.
1 shared publication Amy P. Witte
Department of Pharmacy Practice, University of the Incarnate Word Feik School of Pharmacy, San Antonio, TX, USA
1 shared publication- April Peterson1 shared publication
- Brittany Palasik Torres
College of Pharmacy, The University of North Texas Health Science Center, Fort Worth, TX, USA
1 shared publication - Caitlin M. Gibson
Virginia Commonwealth University School of Pharmacy
1 shared publication - Crystal K. Howell
UNT Health Fort Worth College of Pharmacy Fort Worth Texas USA
1 shared publication
Latest Publications
- 5 November 2025
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 61 (3) , 220-222
Impact of an Additional Therapy Guideline-Directed Medical Therapy on 30-Day Readmissions for Heart Failure with Reduced Ejection Fraction
- 5 November 2025
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 61 (3) , 220-222
Impact of an Additional Therapy Guideline-Directed Medical Therapy on 30-Day Readmissions for Heart Failure with Reduced Ejection Fraction
- 28 June 2023
- Published by SAGE Publications in Journal of Pharmacy Technology
- Vol. 39 (4) , 195-198
Does Emergency Medical Services Blood Collection Shorten Time to Tissue Plasminogen Activator in Ischemic Stroke?
Background: Ischemic stroke is the leading cause of long-term disability in the United States. To reduce the likelihood of debilitating outcomes, early treatment with fibrinolytics is necessary; however, many struggle to identify strategies that limit time to treatment. The purpose of this study is to identify if implementing a process for obtaining laboratory blood draws by emergency medical services (EMS) prior to patient arrival at the hospital will reduce the door-to-needle time for patients arriving with acute ischemic stroke. Objectives: To compare the door-to-needle time for patients with acute ischemic stroke who had blood drawn via EMS versus in hospital. Methods: This single-center, retrospective cohort study was conducted from 2015 to 2017 at a 433-bed designated Level II Trauma Center and Comprehensive Stroke Center community hospital. A comprehensive chart review was done via stroke coordinator binders and electronic medical record. Adult patients ≥18 years of age with an acute ischemic stroke diagnosis who met criteria for and received alteplase were included in the study. Patients were excluded if they did not arrive via EMS. The primary end point assessed time to fibrinolytic treatment via door-to-needle times. Results: A total of 66 patients were included with 28 in the EMS laboratory drawn group and 38 in the usual group. Median door-to-needle time was 57.5 ± 19.0 minutes in the EMS group and 55.0 ± 31.9 minutes in the usual care group ( p = 0.818). Conclusions: Collection of blood for laboratories by EMS personnel did not significantly shorten door-to-needle time.
- 28 June 2023
- Published by SAGE Publications in Journal of Pharmacy Technology
- Vol. 39 (4) , 195-198
Does Emergency Medical Services Blood Collection Shorten Time to Tissue Plasminogen Activator in Ischemic Stroke?
Background: Ischemic stroke is the leading cause of long-term disability in the United States. To reduce the likelihood of debilitating outcomes, early treatment with fibrinolytics is necessary; however, many struggle to identify strategies that limit time to treatment. The purpose of this study is to identify if implementing a process for obtaining laboratory blood draws by emergency medical services (EMS) prior to patient arrival at the hospital will reduce the door-to-needle time for patients arriving with acute ischemic stroke. Objectives: To compare the door-to-needle time for patients with acute ischemic stroke who had blood drawn via EMS versus in hospital. Methods: This single-center, retrospective cohort study was conducted from 2015 to 2017 at a 433-bed designated Level II Trauma Center and Comprehensive Stroke Center community hospital. A comprehensive chart review was done via stroke coordinator binders and electronic medical record. Adult patients ≥18 years of age with an acute ischemic stroke diagnosis who met criteria for and received alteplase were included in the study. Patients were excluded if they did not arrive via EMS. The primary end point assessed time to fibrinolytic treatment via door-to-needle times. Results: A total of 66 patients were included with 28 in the EMS laboratory drawn group and 38 in the usual group. Median door-to-needle time was 57.5 ± 19.0 minutes in the EMS group and 55.0 ± 31.9 minutes in the usual care group ( p = 0.818). Conclusions: Collection of blood for laboratories by EMS personnel did not significantly shorten door-to-needle time.
- Open Access
- 21 January 2023
- Published by International Pharmaceutical Federation (FIP) in Pharmacy Education
- Vol. 23 (1) , 127-131
Innovative approach to career pathway mentorship for pharmacy postgraduate training
Introduction: This brief describes the results of two initiatives, a Postgraduate Training Seminar elective course and a P4 Postgraduate Mentorship Programme, on pharmacy residency match rates at a College of Pharmacy. Description of programmes: The Postgraduate Training Seminar elective course was developed to aid third-year pharmacy students interested in residency. The P4 Postgraduate Mentorship Programme was founded to help fourth-year students interested in postgraduate job attainment. Evaluation: For students participating in the elective, College of Pharmacy residency match rates varied in comparison to the national rates (2019: 55% vs 63%; 2020: 67% vs 65%; 2021: 94% vs 77%). In 2021, students who participated in both the elective course and mentorship programme achieved the highest match results compared to the national rate (2019: 38% vs 63%; 2021: 55% vs 77%). Future plans: Both initiatives will continue, with plans for the expansion of mentorship into the earlier years of the curriculum.
- 21 January 2023
- Published by International Pharmaceutical Federation (FIP) in Pharmacy Education
- Vol. 23 (1) , 127-131
Open AccessInnovative approach to career pathway mentorship for pharmacy postgraduate training
Introduction: This brief describes the results of two initiatives, a Postgraduate Training Seminar elective course and a P4 Postgraduate Mentorship Programme, on pharmacy residency match rates at a College of Pharmacy. Description of programmes: The Postgraduate Training Seminar elective course was developed to aid third-year pharmacy students interested in residency. The P4 Postgraduate Mentorship Programme was founded to help fourth-year students interested in postgraduate job attainment. Evaluation: For students participating in the elective, College of Pharmacy residency match rates varied in comparison to the national rates (2019: 55% vs 63%; 2020: 67% vs 65%; 2021: 94% vs 77%). In 2021, students who participated in both the elective course and mentorship programme achieved the highest match results compared to the national rate (2019: 38% vs 63%; 2021: 55% vs 77%). Future plans: Both initiatives will continue, with plans for the expansion of mentorship into the earlier years of the curriculum.
- 2 June 2022
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 57 (1) , 51-54
Hyperglycemia Post-Influenza Vaccine in Patients With Diabetes
Background: There are more than 350 reports of hyperglycemia post-influenza vaccine according to the Vaccine Adverse Effect Reporting System. Only one case report has been published detailing unusual post-vaccination hyperglycemia. The mechanism as to why hyperglycemia may occur post-vaccination has not been fully elucidated. Objective: Primary: To identify hyperglycemia within the first 24 hours of influenza vaccine. Secondary: To identify transient property of hyperglycemia within 4 days after vaccine. Methods: Multicenter prospective cohort study. Recruitment conducted throughout San Antonio, Texas, during 2018-2020 influenza seasons. Patients were included if 18 years or older, had diabetes mellitus, and currently checking their blood glucose daily. Patients excluded if they had a recent medication change that would effect their blood glucose readings. Patients had hemoglobin A1c and blood glucose measured prior to vaccination with a single dose (0.5 mL) of the tri-valent influenza vaccine intramuscularly. Glucose readings were collected within 24 hours post-vaccination and subsequent mornings for 4 days. Results: A total of 34 patients were included. Average patient age was 75 years with 60% white, 30% black, and 10% Hispanic. Median fasting glucose pre-vaccination was significantly lower than the median value 0 to 24 hours post-vaccination (140 vs 203 mg/dL, P < 0.0001). Conclusion and Relevance: Hyperglycemia was noted 0 to 24 hours post-vaccination and was transient in nature with a return to baseline by post-vaccination day 2. This trial was conducted to close a potential gap in counseling regarding the flu vaccine and decrease any potential concern surrounding the vaccine in patients with diabetes that could lead to reduced vaccination rates.
- 2 June 2022
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 57 (1) , 51-54
Hyperglycemia Post-Influenza Vaccine in Patients With Diabetes
Background: There are more than 350 reports of hyperglycemia post-influenza vaccine according to the Vaccine Adverse Effect Reporting System. Only one case report has been published detailing unusual post-vaccination hyperglycemia. The mechanism as to why hyperglycemia may occur post-vaccination has not been fully elucidated. Objective: Primary: To identify hyperglycemia within the first 24 hours of influenza vaccine. Secondary: To identify transient property of hyperglycemia within 4 days after vaccine. Methods: Multicenter prospective cohort study. Recruitment conducted throughout San Antonio, Texas, during 2018-2020 influenza seasons. Patients were included if 18 years or older, had diabetes mellitus, and currently checking their blood glucose daily. Patients excluded if they had a recent medication change that would effect their blood glucose readings. Patients had hemoglobin A1c and blood glucose measured prior to vaccination with a single dose (0.5 mL) of the tri-valent influenza vaccine intramuscularly. Glucose readings were collected within 24 hours post-vaccination and subsequent mornings for 4 days. Results: A total of 34 patients were included. Average patient age was 75 years with 60% white, 30% black, and 10% Hispanic. Median fasting glucose pre-vaccination was significantly lower than the median value 0 to 24 hours post-vaccination (140 vs 203 mg/dL, P < 0.0001). Conclusion and Relevance: Hyperglycemia was noted 0 to 24 hours post-vaccination and was transient in nature with a return to baseline by post-vaccination day 2. This trial was conducted to close a potential gap in counseling regarding the flu vaccine and decrease any potential concern surrounding the vaccine in patients with diabetes that could lead to reduced vaccination rates.